Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Centelles – page 118

3 673 clinical trials in Centelles, Spain across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Centelles at a glance
3 673
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 673 trials in Centelles

Open in trial search

Study of VSA012 Sodium in Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Complement Inhibitor‑Naïve or Have Persistent Anemia on C5 Inhibitor Therapy

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Bisirna Therapeutics Pte. Ltd.

Study of elranatamab, mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Fundacion Pethema

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Breast cancer+1

Not yet recruiting

Long‑term safety study of alpelisib alone or with fulvestrant in adults with breast cancer who benefited from previous alpelisib treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

A Phase 2 Study of LAD603 in Adults with Systemic Lupus Erythematosus and Active Skin Rash

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:LAD603
  • Sponsor:Almirall S.A.

Plasma cell myeloma

Not yet recruiting

A Phase III Study of AZD0120 versus melphalan hydrochloride with lenalidomide maintenance in transplant‑eligible adults with newly diagnosed multiple myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Safety and Efficacy of Extended‑Release Tacrolimus (VI‑0106) in Adults with Pulmonary Arterial Hypertension and Functional Limitations

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Vivus B.V.

Primary biliary cholangitis

Not yet recruiting

Safety and Efficacy of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis: A Long‑Term Randomized Placebo‑Controlled Study

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Saroglitazar hemimagnesium
  • Sponsor:Zydus Therapeutics Inc.

Diffuse large B-cell lymphoma+5

Not yet recruiting

Study of MDX2003 in Adults with Relapsed or Refractory B‑Cell Malignancies

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:MDX2003
  • Sponsor:Modex Therapeutics Inc.

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Centelles

What the registry says about research in the country

01 Infectious Disease Prevention

Comprehensive research focusing on viral infections including studies evaluating vaccines against SARS-CoV-2, Herpes Zoster, and Cytomegalovirus. Multiple trials are examining vaccine efficacy and immune response in different age groups.

  • COVID-19 Vaccine Development
  • Viral Disease Prevention
  • Vaccine Safety Studies

Special attention is given to vaccine co-administration studies and booster dose evaluations in various populations.

02 Respiratory Health

Innovative clinical research examining treatments for respiratory conditions, including studies on RSV vaccines for older adults and asthma medication delivery systems. These trials aim to enhance treatment options for respiratory diseases.

  • RSV Prevention
  • Asthma Management
  • Pneumococcal Disease

Focus on developing effective preventive measures and treatments for respiratory infections.

03 Cardiovascular Health

Advanced research into cardiovascular disease prevention and treatment, with emphasis on managing hypercholesterolemia and reducing major adverse cardiovascular events. Studies evaluate new therapeutic approaches for heart health.

  • Cholesterol Management
  • Cardiovascular Risk Reduction
  • Preventive Cardiology

Trials focus on innovative medications and preventive strategies for cardiovascular health improvement.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.